tbuckley/cabot-search huggingface dataset:
DOUBLE SEQUENTIAL EXTERNAL DEFIBRILLATION: UNDERUTILIZED IN REFRACTORY ATRIAL FIBRILLATION
Authors: Theodore Richards, Mandar Jagtap, Frank McGrew, Tejaswi Munagala, Linnea Lebaron, Dakshin Gangadharamurthy, Likhitesh Jaikumar
Journal: Journal of the American College of Cardiology (2020)
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
Authors: Luis Paz-Ares, Tae Min Kim, David Vicente, Enriqueta Felip, Dae Ho Lee, Ki Hyeong Lee, Chia-Chi Lin, Maria Jose Flor, Massimo Di Nicola, Rosa Maria Alvarez, Isabelle Dussault, Christoph Helwig, Laureen S. Ojalvo, James L. Gulley, Byoung Chul Cho
Journal: Journal of Thoracic Oncology (2020)
HYPERTENSION GUIDELINES AND CORONARY ARTERY CALCIFICATION AMONG SOUTH ASIANS: MEDIATORS OF ATHEROSCLEROSIS IN SOUTH ASIANS LIVING IN AMERICA (MASALA) AND MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Jaideep Patel, Anurag Mehta, Mahmoud Al Rifai, Michael Blaha, Khurram Nasir, John W. McEvoy, Ambarish Pandey, Alka Kanaya, Namratha R. Kandula, Salim S. Virani, Antonio Abbate, William G. Hundley, Laurence S. Sperling, Parag Joshi
Journal: Journal of the American College of Cardiology (2020)
PROGNOSTIC IMPLICATION OF PAROXYSMAL ATRIAL FIBRILLATION ON PHASE ANALYSIS OF RIGHT ATRIAL FUNCTION IN DEGENERATIVE MITRAL REGURGITATION (DMR)
Authors: Olga Kislitsina, Bonnie Kane, James Thomas, Bradley P. Knight, Andrei Churyla, Andrew Peters, Menghan Liu, Adin-Cristian Andrei, James L. Cox, Patrick McCarthy
Journal: Journal of the American College of Cardiology (2020)
Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme
Authors: Mathilde Cheray, Amandine Etcheverry, Camille Jacques, Romain Pacaud, Gwenola Bougras-Cartron, Marc Aubry, Florent Denoual, Pierre Peterlongo, Arulraj Nadaradjane, Joséphine Briand, Farida Akcha, Dominique Heymann, François M. Vallette, Jean Mosser, Benjamin Ory, Pierre-François Cartron
Journal: Molecular Cancer (2020)

Abstract Background Literature reports that mature microRNA (miRNA) can be methylated at adenosine, guanosine and cytosine. However, the molecular mechanisms involved in cytosine methylation of miRNAs have not yet been fully elucidated. Here we investigated the biological role and underlying mechanism of cytosine methylation in miRNAs in glioblastoma multiforme (GBM). Methods RNA immunoprecipitation with the anti-5methylcytosine (5mC) antibody followed by Array, ELISA, dot blot, incorporation of a radio-labelled methyl group in miRNA, and miRNA bisulfite sequencing were perfomred to detect the cytosine methylation in mature miRNA. Cross-Linking immunoprecipiation qPCR, transfection with methylation/unmethylated mimic miRNA, luciferase promoter reporter plasmid, Biotin-tagged 3’UTR/mRNA or miRNA experiments and in vivo assays were used to investigate the role of methylated miRNAs. Finally, the prognostic value of methylated miRNAs was analyzed in a cohorte of GBM pateints. Results Our study reveals that a significant fraction of miRNAs contains 5mC. Cellular experiments show that DNMT3A/AGO4 methylated miRNAs at cytosine residues inhibit the formation of miRNA/mRNA duplex and leading to the loss of their repressive function towards gene expression. In vivo experiments show that cytosine-methylation of miRNA abolishes the tumor suppressor function of miRNA-181a-5p miRNA for example. Our study also reveals that cytosine-methylation of miRNA-181a-5p results is associated a poor prognosis in GBM patients. Conclusion Together, our results indicate that the DNMT3A/AGO4-mediated cytosine methylation of miRNA negatively. Graphical abstract
31P A study to assess the efficacy and feasibility of adding pioglitazone to imatinib in patients of CML with suboptimal response in a resource-limited setting
Authors: S. Goyal, G. Babu, D. Lokanatha, J.A. Linu, K.N. Lokesh, A.H. Rudresha, L.K. Rajeev, S. Smitha
Journal: Annals of Oncology (2020)
Controversies in Hip Arthroplasty
Authors: Brian R. Hallstrom, Richard E. Hughes
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies
Authors: Katja Haedicke, Lilach Agemy, Murad Omar, Andrei Berezhnoi, Sheryl Roberts, Camila Longo-Machado, Magdalena Skubal, Karan Nagar, Hsiao-Ting Hsu, Kwanghee Kim, Thomas Reiner, Jonathan Coleman, Vasilis Ntziachristos, Avigdor Scherz, Jan Grimm
Journal: Nature Biomedical Engineering (2020)
Simultaneous assessment of targeted anticancer therapy-associated mucocutaneous adverse events.
Authors: Christine Bettine Boers-Doets, Hans Gelderblom, Joel Brian Epstein, Mario E. Lacouture, Ad A Kaptein
Journal: Journal of Clinical Oncology (2013)

e20669 Background: Mucocutaneous adverse events (mcAEs), including papulopustular rash, xerosis, pruritus, paronychia, hand-foot skin reaction, edema, taste alterations, oral pain and ulceration, hair-, periungual-, and ocular changes occur in the majority of patients during targeted anticancer therapies. Different mcAEs can be present with a variable symptom burden and affect upon patients’ quality of life. Use of standardized targeted therapy specific tools allows comparison of outcomes from different studies and in meta-analyses, advancing patient care and improving outcomes. A mcAE specific assessment tool about symptom burden is currently not available. A questionnaire which assesses both targeted therapy specific patient reported outcomes (PRO) measures and healthcare provider reported outcomes (HPRO) measures is warranted, therefore. Methods: A three-phase process was utilized for item generation, item reduction and scale construction. A comprehensive literature review was performed in PubMed, CINAHL and Embase, and study protocols were screened. Keywords were assessment, questionnaire, tool, EGFRI, and rash. All items with potential relevance for the tool were selected for further evaluation. Twentyone EGFRI treated patients filled out the draft-questionnaire. Results: The search resulted in a simultaneous tool in the form of 61 PRO, and 50 HPRO items. Both tools assess experienced mcAEs inclusive number of papules and pustules, area involved, severity and duration of the symptoms, used products, effectiveness of various (medical) interventions, treatment adherence and distress from the symptoms. Patient input resulted in the addition of 1 item, modification of 7 items, and deletion of 2 items. Conclusions: A novel tool has been generated to assess the experienced mcAEs and effectiveness of supportive care interventions. Since the patient and the provider report mcAEs simultaneously, the provided data are directly comparable, facilitating assessment of quality of life and, therefore, improving quality of medical care.
PROGNOSTIC IMPACT OF PULMONARY HYPERTENSION IN PATIENTS WITH SEVERE AORTIC STENOSIS WHO UNDERWENT TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Kimi Sato, Noor Albakaa, Naomi Nakazawa, Masayoshi Yamamoto, Tomoko Machino, Tomoya Hoshi, Akira Sato, Tomoko Ishizu, Masaki Ieda
Journal: Journal of the American College of Cardiology (2020)
Nomogram to predict lymph node metastasis in patients with early gastric cancer: a useful clinical tool to reduce gastrectomy after endoscopic resection
Authors: Su Mi Kim, Byung-Hoon Min, Joong Hyun Ahn, Sin-Ho Jung, Ji Yeong An, Min Gew Choi, Tae Sung Sohn, Jae Moon Bae, Sung Kim, Hyuk Lee, Jun Haeng Lee, Young Woo Kim, Keun Won Ryu, Jae J. Kim, Jun Ho Lee
Journal: Endoscopy (2020)

Abstract Background The indications for endoscopic dissection have been expanded to improve the quality of life of patients with early gastric cancer (EGC). This study aimed to develop a nomogram to predict the status of lymph node metastasis with the aim of avoiding unnecessary gastrectomies. Methods We reviewed the clinicopathological data of 10 579 patients who underwent curative resection for EGC. The nomogram was developed by multivariate analysis and was evaluated by external validation. Overall, disease-free and recurrence-free survival were compared between the gastrectomy group of 6641 patients and the endoscopic dissection group of 999 patients to show the efficacy of the nomogram. Results Multivariate analyses revealed that age, tumor size, lymphatic invasion, depth of invasion, and histologic differentiation were all significant prognostic factors for lymph node metastasis. The nomogram had good discriminatory performance, with a concordance index of 0.846. This was supported by the external validation point of 0.813. For patients with low risk of lymph node metastasis on the nomogram (≤ 3 % of the provisional value in this study), the endoscopic dissection and gastrectomy groups had comparable rates of overall (P = 0.32), disease-free (P = 0.47), and recurrence-free (P = 0.09) survival. Conclusions We developed and validated a nomogram that predicts the risk of lymph node metastasis in EGC based on a large database. This precision nomogram is useful to avoid unnecessary gastrectomy after endoscopic dissection, which may ultimately improve the quality of life of patients with EGC.
Clinical prognostic factors associated with outcome in renal cell cancer (RCC) patients treated with modified vaccinia ankara plus tumor-associated antigen 5T4 (MVA-5T4).
Authors: Prasamsa Pandey, Youxin Xiong, Yufeng Zhang, Mika Stepankiw, Robert J. Amato
Journal: Journal of Clinical Oncology (2013)

e15545 Background: Development of MVA-5T4 as an immunotherapeutic vaccine led to studies demonstrating it is safe and highly immunogenic as a monotherapy or combination (Amato 2008 Clin Cancer Res, Amato 2008 J Immunother, Amato 2009 J Immunother). Antitumor activity has been minimal. We examined identifiable clinical factors to develop a prognostic model to select patients for vaccine immunotherapy. Methods: Clinical data from 3 phase II studies were received for a total of 50 patients treated with MVA-5T4 alone, MVA-5T4 plus interferon-α or MVA-5T4 plus interleukin-2. Kaplan-Meier method was used to calculate progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analyses were constructed using COX Proportional Hazard model and step-wise procedure. The model was validated by measuring the overall concordance index. Results: For the entire population, median PFS was 3.6 months (range 0.9-42.8 months), and median OS was 12.4 months (range 1.0-45.6 months). Univariate analysis revealed 10 clinical factors associated with PFS and 9 clinical factors associated with OS. Multivariate analysis identified 5 factors associated with PFS benefit (ECOG status ≥1, lymphocytes &lt;25, &gt;2 metastatic sites, neutrophils ≥69, albumin &lt;4) and 6 factors associated with OS benefit (ECOG status ≥1, &gt;2 metastatic sites, neutrophils ≥69, platelets &gt;300, prior treatment with tyrosine kinase inhibitors/immunotherapy, Furham grade of 3/4). The prognostic model was divided into 3 categories. Patients with 0-1 factors (favorable) had a median PFS of 9.4 months and OS of 26.2 months, patients with 2-3 factors (intermediate) had a median PFS of 3.0 months and OS of 9.1 months, and patients with 4+ factors (poor) had a median PFS of 2.0 months and OS of 2.0 months. Conclusions: This analysis identified 7 available clinical factors that can classify patients with mRCC into 3 risk groups with various outcomes. Further validation of this model will identify which patients most likely to respond to MVA-5T4 as well as other vaccines. This will allow for the appropriate application of treatment to patients most likely to benefit.
Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK
Authors: Trung N. Tran, Elizabeth King, Rajiv Sarkar, Cassandra Nan, Annalisa Rubino, Caroline O'Leary, Ruvimbo Muzwidzwa, Laura Belton, Jennifer K. Quint
Journal: European Respiratory Journal (2020)

Oral corticosteroids (OCS) are used to manage asthma exacerbations and severe, uncontrolled asthma, but OCS use is associated with adverse effects. We aimed to describe the patterns of OCS use in the real-world management of patients with asthma in western Europe. We used electronic medical records from databases in France, Germany, Italy and the United Kingdom from July 2011 through February 2018. Patients aged ≥12 years with an asthma diagnosis, at least one non-OCS asthma medication within ±6 months of diagnosis, and available data ≥6 months prior to and ≥90 days after cohort entry were included. High OCS use was defined as OCS ≥450 mg prescribed in a 90-day window during follow-up. Baseline characteristics and OCS use during follow-up were described overall and by OCS use status. Of 702 685 patients with asthma, 14–44% were OCS users and 6–9% were high OCS users at some point during follow-up. Annual prevalence of high OCS use across all countries was ∼3%. High OCS users had a mean of between one and three annual OCS prescriptions, with an average daily OCS dosage of 1.3–2.2 mg. For patients who continued to meet the high-use definition, daily OCS exposure was generally stable at 5.5–7.5 mg for ≥2 years, increasing the risk of adverse effects. Our study demonstrates that OCS use is relatively common across the four studied European countries. Data from this study may provide decisive clinical insights to inform primary care physicians and specialists involved in the management of severe, uncontrolled asthma.
POLARIMETRIC SIGNATURES OF VASCULAR TISSUE RESPONSE FOLLOWING DRUG-ELUTING STENT IMPLANTATION IN PATIENTS
Authors: Kenichiro Otsuka, Martin Villiger, Laurens van Zandvoort, Tara Neleman, Antonios Karanasos, Jouke Dijkstra, Evelyn Regar, Seemantini Nadkarni, Joost Daemen, Brett Bouma
Journal: Journal of the American College of Cardiology (2020)
Feasibility of using the drug-induced apoptosis assay (MiCK assay) in mesothelioma as compared to non-small cell lung cancer (NSCLC).
Authors: Dennis A. Wigle, Allan Hallquist, Cary Presant, Julian R. Molina
Journal: Journal of Clinical Oncology (2013)

e18538 Background: The drug-induced apoptosis MiCK assay has been predictive of outcomes in acute myelocytic leukemia, ovarian cancer, and a variety of solid tumors including breast cancer (Cancer Research 2012; 72:3901). We compared MiCK assay results in mesothelioma patients (pts) with NSCLC pts. Methods: Specimens from tissue or effusions were submitted to a central lab, processed to purify neoplastic cells, and a MiCK assay was performed as described (Cancer 2012; 118: 4877). Best chemotherapy regimens are defined as drugs/combinations with highest kinetic units (KU) of apoptosis +/- 1 SD compared to other drugs (this definition was predictive of outcomes in ovarian cancer). Active drugs have results over 1.0 KU of apoptosis. Results: 10 specimens have been submitted and 7 have been successful. Mean age was 69 and mean number of prior lines of therapy were 0.7 in 3 mesothelioma pts and 2.0 in 4 NSCLC pts. Mean number of drugs or combinations assayed successfully were 41 in mesothelioma and 20 in NSCLC. In mesothelioma, best active chemotherapy regimens (&gt;1.0 KU) have been pemetrexed+doxorubicin, epirubicin, idarubicin, cyclophosphamide, ifosfamide, and dactinomycin. In NSCLC, best active regimens have been doxorubicin+cisplatin, irinotecan, and cyclophosphamide+doxorubicin+vincristine. In mesothelioma pts, the assay has been able to identify unexpected significant activity of several drugs: epirubicin, idarubicin, daunorubicin, dactinomycin, bendamustine, melphalan, vincristine, topotecan, azacytidine and bortezomib. Conclusions: Use of the MiCK assay in mesothelioma is at least as successful in the laboratory as it is in NSCLC. Unexpected new leads for innovative therapeutic strategies have been identified by the in vitro results. This feasibility study justifies a prospective controlled trial of the MiCK assay in mesothelioma and NSCLC pts. Clinical trials of drugs with unexpected activity are warranted in mesothelioma pts. Clinical trial information: NCT 01770665.
Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA
Authors: T. Grellety, F. Peyraud, N. Sevenet, O. Tredan, N. Dohollou, E. Barouk-Simonet, M. Kind, M. Longy, J.-Y. Blay, A. Italiano
Journal: Annals of Oncology (2020)
Meta-Analysis Reveals Potential Influence of Oxidative Stress on the Airway Microbiomes of Cystic Fibrosis Patients
Authors: Xing Shi, Zhancheng Gao, Qiang Lin, Liping Zhao, Qin Ma, Yu Kang, Jun Yu
Journal: Genomics Proteomics & Bioinformatics (2019)

The lethal chronic airway infection of the cystic fibrosis (CF) patients is predisposed by colonization of specific CF-philic pathogens or the CF microbiomes, but key processes and reasons of the microbiome settlement in the patients are yet to be fully understood, especially their survival and metabolic dynamics from normal to diseased status under treatment. Here, we report our meta-analysis results on CF airway microbiomes based on metabolic networks reconstructed from genome information at species level. The microbiomes of CF patients appear to engage much more redox-related activities than those of controls, and by constructing a large dataset of anti-oxidative stress (anti-OS) genes, our quantitative evaluation of the anti-OS capacity of each bacterial species in the CF microbiomes confirms strong conservation of the anti-OS responses within genera and also shows that the CF pathogens have significantly higher anti-OS capacity than commensals and other typical respiratory pathogens. In addition, the anti-OS capacity of a relevant species correlates with its relative fitness for the airways of CF patients over that for the airways of controls. Moreover, the total anti-OS capacity of the respiratory microbiome of CF patients is collectively higher than that of controls, which increases with disease progression, especially after episodes of acute exacerbation and antibiotic treatment. According to these results, we propose that the increased OS in the airways of CF patients may play an important role in reshaping airway microbiomes to a more resistant status that favors the pre-infection colonization of the CF pathogens for a higher anti-OS capacity.
MACHINE LEARNING ALGORITHMS TO PREDICT 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR RISK IN A CONTEMPORARY, COMMUNITY-BASED HISTORICAL COHORT
Authors: Jose Medina-Inojosa, Michal Shelly, Zachi Itzhak Attia, Peter Noseworthy, Suraj Kapa, Paul Friedman, Francisco Lopez-Jimenez
Journal: Journal of the American College of Cardiology (2020)
Early mobilisation during extracorporeal membrane oxygenation was safe and feasible: a pilot randomised controlled trial
Authors: Carol L. Hodgson, Kate Hayes, Matthew Linnane, Oystein Tronstad, Nazmeen Reddy, Meredith Young, Heidi Buhr, Natalie J. Linke, Daniel M. Engeler, Bentley J. Fulcher, Alisa M. Higgins, Jayne Sheldrake, Jamie Cooper, Michael J. Bailey, Vincent A. Pellegrino
Journal: Intensive Care Medicine (2020)
HSR20-092: “Write to Recover”: The Impact of Group Led Creative Writing on Physical Health Outcomes in Cancer Patients
Authors: Courtney Ann Kramer, Darya S. Nesterova, Junjia Zhu, Monali Vasekar, Jolene Collins, Cristina Truica, Aditya Joshi, Michael Hayes, Erika F. H. Saunders, Joseph J. Drabick, Monika Joshi
Journal: Journal of the National Comprehensive Cancer Network (2020)
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial
Authors: Jonathan W. Cunningham, João Pedro Ferreira, Hsiaowei Deng, Stefan D. Anker, William M. Byra, John G.F. Cleland, Mihai Gheorghiade, Carolyn S.P. Lam, David La Police, Mandeep R. Mehra, James D. Neaton, Theodore E. Spiro, Dirk J. van Veldhuisen, Barry Greenberg, Faiez Zannad
Journal: JACC Heart Failure (2020)
LONG TERM FOLLOW-UP OF PATIENTS WITH COARCTATION OF THE AORTA
Authors: Philicia Moonsamy, Ami B. Bhatt, Navyatha Mohan, Masaki Funamoto, Serguei Melnitchouk, David A. D'Alessandro, George Tolis, Thoralf M. Sundt, Duke E. Cameron, Arminder Jassar
Journal: Journal of the American College of Cardiology (2020)
COMPARISON OF SHORT-TERM, MID-TERM AND LONG-TERM MORTALITY IN PATIENTS WITH UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE TREATED WITH DRUG-ELUTING STENTS VS. BYPASS SURGERY: INSIGHTS FROM AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Amartya Kundu, Partha Sardar, Satyaki Chakrabarty, Abdalla Hassan, Adedotun Ogunsua, Waqas Qureshi
Journal: Journal of the American College of Cardiology (2020)
Re: Sex-based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.
Authors: A. Avenell, C. Robertson, B. Boachie, F. Stewart, D. Archibald, F. Douglas, P. Hoddinott, Edwin Van Teijlingen
Journal: BMJ (2016)

This is an online-posted   comment to the article published with DOI 10.1136/bmj.i5826

The rapid response itself does not have a DOI, only the URL (https://www.bmj.com/content/355/bmj.i5826/rr)
CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells
Authors: Rebecca F. Rogers, Michael I. Walton, Daniel L. Cherry, Ian Collins, Paul A. Clarke, Michelle D. Garrett, Paul Workman
Journal: Cancer Research (2020)

Abstract Checkpoint kinase 1 (CHK1) is a key mediator of the DNA damage response that regulates cell-cycle progression, DNA damage repair, and DNA replication. Small-molecule CHK1 inhibitors sensitize cancer cells to genotoxic agents and have shown single-agent preclinical activity in cancers with high levels of replication stress. However, the underlying genetic determinants of CHK1 inhibitor sensitivity remain unclear. We used the developmental clinical drug SRA737 in an unbiased large-scale siRNA screen to identify novel mediators of CHK1 inhibitor sensitivity and uncover potential combination therapies and biomarkers for patient selection. We identified subunits of the B-family of DNA polymerases (POLA1, POLE, and POLE2) whose silencing sensitized the human A549 non–small cell lung cancer (NSCLC) and SW620 colorectal cancer cell lines to SRA737. B-family polymerases were validated using multiple siRNAs in a panel of NSCLC and colorectal cancer cell lines. Replication stress, DNA damage, and apoptosis were increased in human cancer cells following depletion of the B-family DNA polymerases combined with SRA737 treatment. Moreover, pharmacologic blockade of B-family DNA polymerases using aphidicolin or CD437 combined with CHK1 inhibitors led to synergistic inhibition of cancer cell proliferation. Furthermore, low levels of POLA1, POLE, and POLE2 protein expression in NSCLC and colorectal cancer cells correlated with single-agent CHK1 inhibitor sensitivity and may constitute biomarkers of this phenotype. These findings provide a potential basis for combining CHK1 and B-family polymerase inhibitors in cancer therapy. Significance: These findings demonstrate how the therapeutic benefit of CHK1 inhibitors may potentially be enhanced and could have implications for patient selection and future development of new combination therapies.